Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Author(s): John Gibbs, Sameer Doshi, Mita Kuchimanchi, Anita Grover, Maurice Emery, Michael Dodds, Megan Gibbs, Ransi Somaratne, Scott Wasserman, Dirk Blom

Year: November 15, 2016

Back to top